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High-intensity focused ultrasound for the
treatment of fibroadenomata (HIFU-F) study
Mirjam C L Peek, Muneer Ahmed and Michael Douek*
Abstract
Background: Breast fibroadenomata (FAD) are the most common benign lesions in women. For palpable lesions,
there are currently three standard treatment options: reassurance (with or without follow-up), vacuum-assisted
mammotomy (VAM) or surgical excision. High-intensity focused ultrasound (HIFU) ablation has been used in the
treatment of FAD. The drawback of HIFU is its prolonged treatment duration. The aim of this trial is to evaluate
circumferential HIFU treatment for the effective ablation of FAD with a reduced treatment time.
Methods/design: Fifty patients (age ≥18 years) will be recruited with symptomatic FAD, visible on ultrasound (US,
grade U2 benign). In patients ≥25 years, cytology or histology will be performed to confirm the diagnosis of a FAD.
These patients will receive HIFU treatment using the US-guided Echopulse device (Theraclion Ltd., Malakoff, France)
under local anaesthesia. An additional 50 patients will be recruited and contacted 6 months after discharge from
the breast clinic. These patients will be offered an US scan to determine the change in size of their FAD. This natural
change in size will be compared to the decrease in size after HIFU treatment. Secondary outcome measures include
post-treatment complications, patient recorded outcome measures, mean treatment time and cost analysis.
Trial registration: Current Controlled Trials: ISRCTN76622747.
Keywords: Ultrasound-guided high-intensity focused ultrasound (HIFU), Benign breast disease, Fibroadenoma,
Non-invasive treatment
Background
Fibroadenomata (FAD) are the most common benign
breast lesions in women. FAD can occur at any age but
are most common between 20 and 30 years of age. FAD
occur in about 10% of all woman and account for about
50% of all breast biopsies performed [1]. Studies revealed
that up to 59% of FAD will show regression or complete
resolution within 5 years [1]. Malignant transformation
within FAD is considered exceptionally rare (0.002%–
0.0125%) and there is a 1.3–2.1 increased risk of breast
cancer in women with FAD compared to the general
population [2]. FAD are encapsulated from their sur-
rounding tissues and can be considered as an aberration
of normal breast development rather than a true neo-
plasm. On histology, FAD consist of combined prolifera-
tion of epithelial and fibroblastic tissue elements which
are slowly growing and oestrogen dependent [3,4].
The diagnosis of a FAD can be made by standard triple
assessment (clinical examination, imaging and histopath-
ology). During clinical examination, 50%–67% of breast
lesions identified as a FAD are confirmed as FAD on im-
aging and/or histopathology due to similar characteris-
tics with other benign conditions [5,4]. Therefore, more
accurate diagnostic methods are required to get the cor-
rect diagnosis. Ultrasound (US) is the main diagnostic
imaging modality used for the diagnosis of FAD [5], and
fine needle aspiration cytology (FNAC) or core needle
biopsy (CNB) can be used to get tissue confirmation of
the diagnosis. The overall diagnostic accuracy of this
triple assessment is approximately 70%–80%, but an ac-
curate differentiation between a benign and a malignant
lesion is provided in 95% [5,4].
The management of non-palpable FAD is conservative
with reassurance. For palpable FAD, there are currently
three main treatment options available: reassurance
(with or without follow-up), vacuum-assisted mammot-
omy (VAM) and surgical excision. VAM is not officially
licensed for the treatment of FAD only to obtain the
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diagnosis of a lesion. Intervention is normally offered to
patients with large FAD or rapidly growing lesions or to
patients requesting excision of the lesion due to anxiety,
discomfort or breast distortion [4]. In other cases, surgi-
cal removal can cause scarring and poor cosmetic out-
come [5,6].
A new technique in the treatment of FAD is high-
intensity focused ultrasound (HIFU) ablation. This is a
non-invasive ablative technique in which the FAD is
treated with focused consecutive repeated US pulses,
while surrounding tissues are protected from the applied
heat.
The basis of HIFU therapy is a HIFU pulse of several
seconds generated by a piezoelectric US transducer. The
US field is insonated via a coupling media overlaying the
tissue to the targeted area. Due to the high local concen-
tration of acoustic energy in the focal spot, the tissue in
a small volume is heated rapidly, and a sharp circum-
scribed lesion caused by thermal coagulation will be in-
duced [7]. HIFU has been clinically applied for the
treatment of invasive breast cancer and demonstrated
coagulative necrosis on pathological assessment, regres-
sion of tumour size and loss of proliferative activity with
a minimal side effect profile [8-16]. Pathological examin-
ation with Victoria Blue and Ponceau histochemical
staining has been used to assess tumour vascular wall
destruction and immunohistochemical staining for pro-
liferative markers using biotin-streptavidin-peroxidase
[13]. Cell viability has been determined by staining for
active dehydrogenase using 2,3,5-triphenyltetrazolium
chloride (TTC) [14].
The current limitation of HIFU is the prolonged treat-
ment duration associated with the procedure. Since a
single pulse generates a rather small tissue lesion, a lot
of these consecutive repeated pulses have to be applied
with an adequate idle time in between to prevent over-
heating and damage to normal tissue [7]. We propose to
overcome the prolonged treatment duration by applying
HIFU pulses to the circumferential surface area of the
lesion rather than their whole volume. We propose to
perform this upon a cohort of patients with benign
breast tumours in the form of FAD using the US-guided
EchopulseTM (Theraclion Ltd., Malakoff, France) HIFU
system, which is CE marked for the treatment of breast
FAD.
Methods/design
Patients
We will undertake treatment on 50 patients with con-
firmed FAD. Patients will be identified in three ways: (1)
at multidisciplinary meetings (MDM), where all patients
who undergo CNB or FNAC are discussed; (2) patients
scheduled for surgical excision of a FAD; and (3) pa-
tients visiting the Breast Clinic requesting surgical
excision. All patients will be approached in the Breast
Clinic or via telephone asking if they are interested in
receiving a patient information sheet on the HIFU-F trial
which describes the procedure in detail. If patients are
interested, a second telephone call will be made to check
if the patient would like to participate in the study and
to answer any questions. Patients who are willing to par-
ticipate in the study will provide informed written con-
sent on the day of elective surgery or at a prior hospital
visit (during pre-assessment). Details of all patients
approached about the trial will be recorded on the
patient-screening log and kept in the Investigator Site
File.
Inclusion and exclusion criteria
Patients eligible for this trial are patients ≥18 years of
age with FAD diagnosed according to local hospital
protocol visible on US (graded U2 benign). In patients
≥25 years of age, confirmation is required by either
FNAC (C2) or CNB (B2) (Figure 1). The definitive diag-
nosis of FAD must be confirmed by the breast MDM.
Exclusion criteria are FAD with atypia or suspicion of
phyllodes (graded B3/C3 or greater), pregnant or lactat-
ing women, women with breast implants and women
with a history of laser or radiation therapy to the tar-
geted breast.
HIFU treatment group
All patients in the HIFU treatment group will attend the
HIFU treatment using the US-guided Echopulse device
(Theraclion Ltd., Malakoff, France) as a day-case proced-
ure to be performed in the Clinical Research Facility
(CRF) at Guy’s Hospital. The breast lesions will be ab-
lated real-time under US guidance using a 7.5–12-MHz
diagnostic US transducer (Theraclion Ltd., Malakoff,
France). This device produces therapeutic US energy by
a 56 ± 1 mm diameter 3.0-MHz imaging transducer with
a central hole of 11 ± 1 mm for the coaxial imaging
transducer. The transducer ablates a tissue volume of
approximately 9 mm in length and 2 mm in width.
Patients will be placed in a supine position and degassed
local anaesthetic will be administered subcutaneously
under US guidance. The breast will be immobilised when
necessary with an immobilisation system (Theraclion Ltd.,
Malakoff, France). A coupling media in the form of a gel
pad attached to the device will be lowered onto the treat-
ment site. The Echopulse™ will be used to image the lesion
in two perpendicular dimensions and set to deliver HIFU
to the circumferential surface area of the lesion by dese-
lecting the centre of the lesion. A laser pointer detects any
significant movement from the patient and pauses the
treatment. Treatment times at beginning (first pulse ad-
ministered) and end (last pulse administered) of the treat-
ment will be recorded. Actual treatment time will be
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compared to the treatment time required for complete
whole-lesion ablation. Once the treatment is complete,
the patient will be observed in the discharge suite before
being discharged. All patients will be reviewed post-
treatment at 2 weeks and 3, 6 and 12 months with a repeat
US scan at each appointment.
Patients who have not experienced at least a 50% re-
duction in volume of their FAD at 6 months follow-up
on US will be offered the opportunity to undergo an
additional HIFU treatment.
Control group
Another 50 patients with symptomatic palpable FAD
who have been discharged from the Breast Clinic since
the HIFU-F trial started (12 December 2013) will be re-
cruited. These patients will be contacted 6 months after
their discharge and will be offered an US scan in order
to determine the change in volume of their FAD.
This cohort will be selected in order to identify the
natural course of FAD over a period of 6 months from
diagnosis. Analysis will be performed to compare the dif-
ference in volume between the HIFU-treatment group
versus control group initially when 20 control patients
have been recruited.
Outcome measures
The primary outcome measure is the change in volume
of FAD as recorded by US. Secondary outcome measures
will include complications, patient-recorded outcome
measures, mean treatment time and cost-effectiveness of
the HIFU treatment compared to surgical excision.
All patients will be asked prior to receiving HIFU
treatment and again at 6 and 12 months post-treatment
to submit sections of the Breast-Q Breast Conserving
Therapy Modules to assess patient-recorded outcome
measures.
A two-sample T-test will be performed to determine if
there is a significant difference in FAD volume reduction
between the study group and the control group. To de-
termine if the variances are equal or unequal, we will
perform a two-sample F-test. A two-sample T-test will
also be used to determine if there is a significant reduc-
tion in lesion volume at 6 months compared to prior to
treatment.
Discussion
At our unit, over 600 FAD were identified on US im-
aging in 2012 of which 6 underwent VAM and 60 formal
surgical excision. Difficulties could be encountered dur-
ing recruitment of patients from the MDM. Clinicians
Figure 1 HIFU-F trial scheme.
Peek et al. Journal of Therapeutic Ultrasound  (2015) 3:6 Page 3 of 5
could be hesitant to allow recruitment of patients who
have symptomatic FAD, but would not generally be of-
fered intervention. Patients offered surgical excision are
usually patients with atypical FAD, lesions with a suspi-
cion of phyllodes tumour and fast growing and large
FAD. Most of these patients are not eligible for HIFU
treatment and should be offered surgical excision. Large
lesions are not an exclusion criteria, but HIFU treatment
would take significantly longer and multiple treatments
might be needed to treat the whole FAD.
In general, FNAC and CNB could be performed in all
patients; however, local protocol permits women
<25 years of age in which US and physical examination
reveals a solid lesion with typical benign characteristics
to omit histopathology. This is due to the low incidence
of breast cancer in woman of this age group [17,18].
The primary outcome measure is the volume decrease
of the FAD as visible on US. US is the standard diagnos-
tic imaging modality for FAD and accessible to patients
and staff. Furthermore, the FAD must be visible on US
to be eligible for HIFU; it should therefore be possible to
visualise and measure the FAD post-treatment as well.
Disadvantages of US as an imaging modality are the
inter-observer variability between the measurements
performed by different ultrasonographers. The ideal im-
aging modality would be accessible and overcome inter-
observer variability.
In this protocol, the diameters of the FAD are mea-
sured in three dimensions to calculate the volume of the
FAD with formula (1), in which A, B and C are the lar-
gest diameters in the three dimensions.
V ¼ 4
3
 π  1
2
A
 
 1
2
B
 
 1
2
C
 
ð1Þ
Measuring one diameter is not sufficient since the
decrease enough since the decrease in size could be dif-
ferent in the different dimensions, and with the volume,
these are all taken into account.
The disadvantage of this trial is that no histology or
cytology is obtained post-treatment. Only in patients
opting for surgical excisions after HIFU treatment could
the histology be obtained. Histopathology could provide
more accurate information about the changes in FAD
size and surrounding tissues over time. CNB or FNAC
could be performed to obtain this as well; however, these
would likely hamper recruitment.
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